BNGO
Bionano Genomics names Dr. Albert Luderer as Interim CEO and Chairman.
Dr. Albert Luderer, PhD, assumed the roles of Chairman and Interim Chief Executive Officer at Bionano Genomics effective September 14, 2026.
BNGO news
Latest 4 stories · newest Sep 14, 2026
BNGO
Bionano Reports Q2 2026 Results, Eliminates Debt
Bionano Genomics beat revenue expectations on strong clinical OGM adoption and retired all secured convertible debentures during the quarter.
BNGO
Bionano Genomics appoints Dr. Alex Hastie as Chief Scientific Officer
Bionano Genomics announced the hiring of Alex Hastie, Ph.D., as Chief Scientific Officer, effective July 20, 2026. His return signals a strategic focus on advancing optical genome mapping and research applications in oncology.
BNGO
Bionano retires $20M convertible debentures, eliminates secured debt
Bionano Genomics fully retired all outstanding Senior Secured Convertible Debentures using cash on hand, eliminating all secured debt obligations and asset liens. The move removes financial constraints and provides greater operational flexibility for the company to focus on commercial growth of its …
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same BNGO feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/BNGO/newsSTART FREE